Genetic markers for the efficacy of tumour necrosis factor blocking therapy in rheumatoid arthritis

Annals of the Rheumatic Diseases

Volumn 62, Issue 6, 2003, Pages 526-529

  Padyukov, L ^a,b   Lampa, J ^b   Heimburger M ^b   Ernestam, S ^b   Cederholm, T ^b   Lundkvist, I ^b   Andersson, P ^b   Hermansson, Y ^b   Harju, A ^b   Klareskog, L ^b   Bratt, J ^b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; ETANERCEPT; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR BLOCKING AGENT; UNCLASSIFIED DRUG;

ADULT; AGED; ALLELE; ARTICLE; CODON; DISEASE ACTIVITY; DRUG EFFICACY; DRUG RESPONSE; FEMALE; GENETIC MARKER; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; INTRON; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; RHEUMATOID ARTHRITIS;

ADULT; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CYTOKINES; FEMALE; GENETIC MARKERS; GENOTYPE; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; PATIENT SELECTION; POLYMORPHISM, GENETIC; PROGNOSIS; RECEPTORS, TUMOR NECROSIS FACTOR; RECOMBINANT FUSION PROTEINS; TREATMENT OUTCOME;

EID: 0038823966     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.62.6.526     Document Type: Article

References (26)

1. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
2. Choy EH, Panayi GS. Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med 2001;344:907-16.
3. Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, Keystone EC, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000;343:1586-93.
4. Maini R, St Clair EW, Breedveld F, Furst D, Kalden J, Weisman M, et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 1999;354:1932-9.
5. Weyand CM, Hicok KC, Conn DL, Goronzy JJ. The influence of HLA-DRB1 genes on disease severity in rheumatoid arthritis. Ann Intern Med 1992;117:801-6.
6. Gough A, Faint J, Salmon M, Hassell A, Wordsworth P, Pilling D, et al. Genetic typing of patients with inflammatory arthritis at presentation can be used to predict outcome. Arthritis Rheum 1994;37:1166-70.
7. Thomson W, Harrison B, Ollier B, Wiles N, Payton T, Barrett J, et al. Quantifying the exact role of HLA-DRB1 alleles in susceptibility to inflammatory polyarthritis: results from a large, population-based study. Arthritis Rheum 1999;42:757-62.
8. Ulfgren AK, Grondal L, Lindblad S, Khademi M, Johnell O, Klareskog L, et al. Interindividual and intra-articular variation of proinflammatory cytokines in patients with rheumatoid arthritis: potential implications for treatment. Ann Rheum Dis 2000;59:439-47.
9. Lard LR, Vos KK, Zwinderman AH, Hazes JMW, Breedveld FC, Schreuder G, et al. Influence of HLA class II and autoantibodies on treatment effects of newly diagnosed rheumatoid arthritis patients [abstract]. Arthritis Rheum 2000;43(suppl):S402.
10. Ulfgren AK, Andersson U, Engstrom M, Klareskog L, Maini RN, Taylor PC. Systemic anti-tumor necrosis factor alpha therapy in rheumatoid arthritis down-regulates synovial tumor necrosis factor alpha synthesis. Arthritis Rheum 2000;43:2391-6.
11. Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995;38:727-35.
12. Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995;38:44-8.
13. Aldener-Cannava A, Olerup O. HLA-DPA1 typing by PCR amplification with sequence-specific primers (PCR-SSP) and distribution of DPA1 alleles in Caucasian, African and Oriental populations. Tissue Antigens 1996;48:153-60.
14. Tarlow JK, Blakemore AI, Lennard A, Solari R, Hughes HN, Steinkasserer A, et al. Polymorphism in human IL-1 receptor antagonist gene intron 2 is caused by variable numbers of an 86-bp tandem repeat. Hum Genet 1993;91:403-4.
15. Padyukov L, Hahn-Zoric M, Lau YL, Hanson LÅ. Different allelic frequencies of several cytokine genes in Hong Kong Chinese and Swedish Caucasians. Genes Immunlty 2001;2:280-3.
16. Olerup O, Zetterquist H. HLA-DR typing by PCR amplification with sequence-specific primers (PCR- SSP) in 2 hours: an alternative to serological DR typing in clinical practice including donor-recipient matching in cadaveric transplantation. Tissue Antigens 1992;39:225-35.
17. McGuire W, Hill AV, Allsopp CE, Greenwood BM, Kwiatkowski D. Variation in the TNF-alpha promoter region associated with susceptibility to cerebral malaria. Nature 1994;371:508-10.
18. Turner D, Grant S, Yonan N, Sheldon S, Dyer P, Sinnot P, et al. Cytokine gene polymorphism and heart transplant rejection. Transplantation 1997;64:776-9.
19. Perrier S, Coussediere C, Dubost JJ, Albuisson E, Sauvezie B. IL-1 receptor antagonist (IL-1RA) gene polymorphism in Sjögren's syndrome and rheumatoid arthritis. Clin Immunol Immunopathol 1998;87:309-13.
20. Sankaran D, Asderakis A, Ashraf S, Roberts IS, Short CD, Dyer PA, et al. Cytokine gene polymorphisms predict acute graft rejection following renal transplantation. Kidney Int 1999;56:281-8.
21. Awad MR, El-Gamel A, Hasleton P, Turner DM, Sinnott PJ, Hutchinson IV. Genotypic variation in the transforming growth factor-beta1 gene: association with transforming growth factor-beta1 production, fibrotic lung disease, and graft fibrosis after lung transplantation. Transplantation 1998;66:1014-20.
22. Kroeger KM, Carville KS, Abraham LJ. The -308 tumor necrosis factor-alpha promoter polymorphism effects transcription. Mol Immunol 1997;34:391-9.
23. Turner DM, Williams DM, Sankaran D, Lazarus M, Sinnott PJ, Hutchinson IV. An investigation of polymorphism in the interleukin-10 gene promoter. Eur J Immunogenet 1997;24:1-8.
24. Wilson AG, Symons JA, McDowell TL, McDevitt HO, Duff GW. Effects of a polymorphism in the human tumor necrosis factor alpha promoter on transcriptional activation. Proc Natl Acad Sci USA 1997;94:3195-9.
25. Danis VA, Millington M, Hyland VJ, Grennan D. Cytokine production by normal human monocytes: inter-subject variation and relationship to an IL-1 receptor antagonist (IL-1 Ra) gene polymorphism. Clin Exp Immunol 1995;99:303-10.
26. Taylor KD, Plevy SE, Yang H, Landers CJ, Barry MJ, Rotter JI, et al. ANCA pattern and LTA haplotype relationship to clinical responses to anti-TNF antibody treatment in Crohn's disease. Gastroenterology 2001;120:1347-55.